Triple Therapy for Squamous NSCLC Shows Real-World Clinical Benefit Triple Therapy for Squamous NSCLC Shows Real-World Clinical Benefit

Sintilimab immunotherapy is not only effective when combined with gemcitabine and chemotherapy, but it may be a novel option when added to paclitaxel/nab-paclitaxel in squamous non –small cell lung cancer.First Look
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news